Summary
Classic Hodgkin lymphoma (cHL) prognostication primarily relies on clinical and radiological
factors. Despite this, a subset of patients still progress. Immunohistochemistry (IHC)
based biomarkers on diagnostic tissue have not been routinely used for prognostication.
A multicentre retrospective analysis identified 62 patients with cHL. IHC on diagnostic
tissues was used to stain Reed–Sternberg cells (RS) cells for STAT1, pSTAT3, p53 and
tumour microenvironment for CD68 and PD-1. IHC stains were scored by anatomical pathologists
blinded to patients and their outcomes and correlated with survival. Strong intensity
of STAT1 and pSTAT3 staining correlated with improved overall survival (OS), with
hazard ratios (HR) of 0.21 [95% confidence interval (CI) 0.06–0.76] and 0.22 (95%
CI 0.06–0.84), respectively. Similarly, the median OS for weak versus strong STAT1
or pSTAT3 staining was 8.8 years versus not reached. Other IHC stains did not correlate
with prognosis. In this cohort of cHL patients, downregulation of immunohistochemical
STAT1 or pSTAT3 in RS cells is associated with inferior OS, suggesting STAT transcription
within the pathognomonic RS cells may have tumour suppressor function and may be a
potential biomarker for cHL prognosis.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PathologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- SEER Cancer Statistics Review.(1975–2018) National Cancer Institute, Bethesda, MD2021
- Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.Lancet Oncol. 2013; 14: 943-952
- A prognostic score for advanced Hodgkin's disease.N Engl J Med. 1998; 339: 1506-1514
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Blood. 2010; 116: 3268-3277
- Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.Oncogene. 2006; 25: 2679-2684
- Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.Nat Genet. 2014; 46: 329-335
- An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma.Blood. 2019; 134: 591-596
- STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer.J Hematol Oncol. 2021; 14: 198
- Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.Clin Cancer Res. 2014; 20: 2674-2683
- Contribution of STAT1 to innate and adaptive immunity during type I interferon-mediated lethal virus infection.PLoS Pathog. 2020; 16e1008525
- Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.N Engl J Med. 2010; 362: 875-885
- Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden.Oncologist. 2019; 24: 219-228
- Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.Blood. 2018; 131: 2454-2465
- Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.Cancer Res. 1994; 54: 2914-2918
- Predicting STAT1 as a prognostic marker in patients with solid cancer.Ther Adv Med Oncol. 2020; 121758835920917558
- Prognostic role of phospho-STAT3 in patients with cancers of the digestive system: a systematic review and meta-analysis.PLoS One. 2015; 10e0127356
- CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma.Leuk Lymphoma. 2014; 55: 1031-1037
- The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.J Pathol. 2010; 222: 191-198
- Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma.Leuk Lymphoma. 2006; 47: 1932-1940
- The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.Lancet Haematol. 2016; 3: e467-e479
- Role of STAT3 in cancer metastasis and translational advances.Biomed Res Int. 2013; 2013421821
- Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.Cancer Cell. 2015; 27: 516-532
- Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms.J Biol Chem. 2000; 275: 32244-32249
- The opposing function of STAT3 as an oncoprotein and tumor suppressor is dictated by the expression status of STAT3β in esophageal squamous cell carcinoma.Clin Cancer Res. 2016; 22: 691-703
- STAT3beta, a distinct isoform from STAT3.Int J Biochem Cell Biol. 2019; 110: 130-139
- Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.Clin Cancer Res. 2010; 16: 2427-2434
- Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.Clin Cancer Res. 2003; 9: 594-600
- Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis.Br J Cancer. 2003; 89: 344-349
- STAT1 in cancer: friend or foe?.Discov Med. 2017; 24: 19-29
- STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.Leukemia. 2009; 23: 1885
Article info
Publication history
Published online: May 09, 2023
Accepted:
February 23,
2023
Received in revised form:
February 3,
2023
Received:
October 9,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.
